VitD suppresses inflammation in the context of both mild and exaggerated inflammatory reactions.
neutrophilia
NEUTROPHILIA, INFLAMMATORY RESPONSE
We initially established in Among Mild participants at 72hrs P-I, those who were VitD(–) upregulated 10 NM injury markers relative to baseline. Comparatively, Mild VitD(+) participants upregulated only 6 NM injury markers (At 72hrs P-I, Severe VitD(–) and VitD(+) participants each expressed 11 NM injury markers, 9 of which were the same markers (Among 6wks P-I Mild participants, 3 NM injury markers (CCL19, CD5, and CD40) remained persistently upregulated in VitD(–) participants but not VitD(+) participants (The upregulation of inflammatory cytokines would conceivably lead to changes in immunologic parameters during real-world, high-dose exposure to NM. However, we did not anticipate that the low experimental dose of NM used in this study would induce an inflammatory response strong enough to create measurable systemic change. Nevertheless, Severe VitD(–) participants demonstrated a trend toward neutrophilia after the second NM exposure, evidenced by an increase (Serum studies also suggest that the metabolism of exogenous, high-dose VitD may differ depending on the recipient’s underlying inflammatory profile. Under normal physiologic conditions, serum 1,25(OH)